Future Outlook of the Biologics CDMO Market: Growth, Trends, and Emerging Opportunities Explored
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the biologics cdmo market?
The increase in the size of the biologics CDMO market has been swift in the past few years. It’s predicted to expand from $21.3 billion in 2024 to an estimated $24.37 billion in 2025, boasting a compound annual growth rate (CAGR) of 14.4%. The escalation during the historical period owes its success to factors such as the elevating development in biologics, cost-effectiveness and versatility, concentration on key proficiencies, regulatory adherence and quality assurance, as well as the worldwide propagation of pharmaceutical supply chains.
What will be the biomass boilers market size in the future?
The market size of biologics cdmo is projected to experience accelerated growth in the upcoming years. By 2029, it’s estimated to expand to a monumental $42.33 billion, with a compound annual growth rate (CAGR) of 14.8%. The growth predicted within this timeframe can be credited to factors such as the rising demand for biologic therapies, the development of biosimilars and biobetters, infrastructural investments in biomanufacturing, a shift towards outsourcing more complex procedures, enhancing supply chain resilience and risk prevention strategies, regulatory harmony, and fast-track approvals. About the forecast period, the primary trends to expect consist of the broadening of capabilities to deliver comprehensive solutions, the implementation of single-use technologies, the integration of ongoing manufacturing procedures, and the emergence of specialized CDMOs.
Get your biologics cdmo market report here!
https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report
What main drivers are fueling expansion in the biologics cdmo market?
The rising demand for cell and genetic therapy is predicted to fuel the expansion of the biologic CDMO market. These advanced therapeutic methods employ living cells or genetic substances to target disease origins at the cellular or genetic level, potentially providing answers for diseases that are challenging to control or untreatable with conventional pharmaceuticals. The demand for these therapies is increasing due to their ability to provide groundbreaking treatments by dealing with the root genetic or cellular causes. Biologic CDMOs have the expertise to manage living cells, viral vectors, and genetic substances, ensuring the safe and effective manufacturing of cell and gene therapies. They also assist biopharmaceutical companies in understanding regulatory requirements and technical obstacles, thus easing the transition from research to clinical application. For instance, The American Society of Gene & Cell Therapy (ASGCT), reported in January 2023 that the gene, cell, and RNA therapy pipeline expanded by 7% in 2022, with a total of 3,726 therapies under development. These included 55% gene therapies, 22% non-genetically modified cell therapies, and 23% RNA therapies. As a result, the escalating demand for cell and genetic therapy is propelling the biologic CDMO market’s growth.
What key areas define the segmentation of the global biologics cdmo market?
The biologics cdmo market covered in this report is segmented –
1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type: Biologics, Biosimilars
Subsegments:
1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp
Who are the dominant players expanding their reach in the biologics cdmo market?
Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.
How are evolving market trends shaping biologics cdmo Strategies?
Leading firms in the biologics CDMO market are creating sophisticated technological solutions, like the development of novel cell lines, to improve the efficiency and capabilities of biopharmaceutical development and production processes. This tech contributes to the creation of potent therapeutic antibodies that are instrumental in addressing challenges faced in immunotherapy research and development. For example, in November 2023, the Swiss-based manufacturing company specialising in pharmaceuticals and biotechnology, Lonza Group, introduced the GS Effex cell lines. These are specifically manufactured to generate antibodies devoid of any fucose, a type of sugar molecule, and exhibit increased potency without any compromise on their other performing characteristics. This innovation assists in dealing with hurdles associated with the augmentation of potency in antibody therapeutics in the sphere of immunotherapy research and development. The GS Effex cell line is a durable, producible, and scalable solution, conducive for therapeutic development right from the discovery-stage research to commercial manufacture.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14056
Which regions are emerging as leaders in the biologics cdmo market?
North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Privileged Access Management Solutions Global Market Report 2024
Multi-Access Edge Computing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/multi-access-edge-computing-global-market-report
Physical Identity And Access Management Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
